{"id":33,"date":"2021-04-02T01:50:51","date_gmt":"2021-04-01T23:50:51","guid":{"rendered":"http:\/\/www.myrpharm.com\/?page_id=33"},"modified":"2024-02-08T10:55:28","modified_gmt":"2024-02-08T09:55:28","slug":"who-we-are","status":"publish","type":"page","link":"https:\/\/www.myrpharm.com\/index.php\/who-we-are\/","title":{"rendered":"Founder"},"content":{"rendered":"\n<p><\/p>\n\n\n\n<p><strong>Conseil en strat\u00e9gie de transfert et de valorisation<\/strong><\/p>\n\n\n\n<p><em>Advisor on transfer and valuation strategy<\/em><\/p>\n\n\n\n<p>Cr\u00e9e en 2020 Myrpharm Advisors vous accompagne dans le d\u00e9veloppement de vos innovations issues de la recherche acad\u00e9mique vers une validation leur permettant une mise sur le march\u00e9.<\/p>\n\n\n\n<p><em>Established in 2020, Myrpharm Advisors supports you in the development of your innovations resulting from academic research towards validation allowing them to be launched on the market.<\/em><\/p>\n\n\n\n<p>Les jeunes startups acad\u00e9miques ou spin-off des grand instituts de recherche ont besoin de soutien afin de pouvoir prendre en compte tous les probl\u00e9matiques li\u00e9es au d\u00e9veloppement d&#8217;innovation pharmaceutiques. <\/p>\n\n\n\n<p><em>Young academic startups or spin-offs from major research institutes need support in order to be able to take into account all the issues related to the development of pharmaceutical innovation.<\/em><\/p>\n\n\n\n<p>Anticiper pour se pr\u00e9munir de probl\u00e8mes dans le d\u00e9veloppent qui s&#8217;av\u00e8re souvent long et fastidieux pour les innovations th\u00e9rapeutiques est un atout majeur. <\/p>\n\n\n\n<p><em>Anticipating in order to guard against development problems, which often turn out to be long and tedious for therapeutic innovations, is a major asset.<\/em><\/p>\n\n\n\n<p>Trouver les bons interlocuteurs, mettre en place les bons accord et les meilleures conditions de partenariats sont la cl\u00e9 de la r\u00e9ussite des premi\u00e8res \u00e9tapes . <\/p>\n\n\n\n<div class=\"wp-block-qubely-team qubely-block-397287\"><div class=\"qubely-block-team  qubely-team-layout-1\"><div class=\"qubely-team-image-wrapper\"><img decoding=\"async\" class=\"qubely-team-image\" src=\"https:\/\/www.myrpharm.com\/wp-content\/uploads\/2021\/04\/Florence-Allouche-scaled.jpg\" srcset=\"\" alt=\"Florence ALLOUCHE AKNIN\"\/><\/div><div class=\"qubely-team-content\"><div class=\"qubely-team-content-inner\"><span class=\"qubely-team-name\">Florence ALLOUCHE AKNIN<\/span><div class=\"qubely-team-designation-container\"><span class=\"qubely-team-designation\"><br>Docteur en Pharmacie, MBA HEC Paris, Florence Allouche Aknin est ancienne attach\u00e9e des H\u00f4pitaux de Paris.<br>Pharmacien en officine, puis dans l\u2019industrie pharmaceutique et du diagnostic, elle a cr\u00e9\u00e9 en 2000 l\u2019Office du Transfert de Technologie et des Partenariats Industriels de l\u2019Assistance Publique &#8211; H\u00f4pitaux de Paris qu\u2019elle a dirig\u00e9 et d\u00e9velopp\u00e9 pendant 16 ans. 1000 brevets d\u00e9pos\u00e9s, 260 licences sign\u00e9es, 25M\u20ac de redevances annuelles 75 startups de Biotech\/Medtech\/diagnostic\/e-health cr\u00e9\u00e9es ce sont les chiffres de cette politique active de transfert et d\u2019essaimage.<br><br>Une des premi\u00e8res administratrices du p\u00f4le de comp\u00e9titivit\u00e9 Medicen, Florence a \u00e9t\u00e9 membre expert des comit\u00e9s de s\u00e9lection des principaux incubateurs d\u2019entreprises franciliens (AGORANOV, Paris Biotech sant\u00e9) et du Comit\u00e9 Strat\u00e9gique de G\u00e9nopole.<br>Repr\u00e9sentante des structures de transfert de technologie en France au sein du r\u00e9seau CURIE dont elle a \u00e9t\u00e9 administrateur, et \u00e0 l\u2019international \u00e0 l\u2019AUTM et l\u2019ASTP Proton, elle a cr\u00e9\u00e9 et port\u00e9 le Domaine de Valorisation Strat\u00e9gique \u00ab\u00a0dispositifs m\u00e9dicaux\u00a0\u00bb au sein du Consortium de Valorisation de l\u2019alliance AVIESAN.<br><br>Professeur associ\u00e9e \u00e0 la Facult\u00e9 de Pharmacie, Universit\u00e9 de Paris, elle a cr\u00e9\u00e9 et dirige depuis 2014, des enseignements sp\u00e9cifiques d\u00e9di\u00e9s \u00e0 l\u2019innovation pharmaceutique, au Transfert de technologie et \u00e0 l\u2019entrepreneuriat.<br>Florence est membre de l&#8217;Acad\u00e9mie Nationale de Pharmacie.<br><br>Florence Allouche Aknin a \u00e9t\u00e9 pr\u00e9sidente de SparingVision, qu\u2019elle a co-fond\u00e9e en 2016 avec le Professeur Jos\u00e9 Alain Sahel, pour valoriser plus de 20 ans de recherche ophtalmique de pointe au sein de l&#8217;Institut Vision \u00e0 Paris. SparingVision est une soci\u00e9t\u00e9 de m\u00e9dicaments g\u00e9nomiques au stade clinique, permettant de sauver la vue. SparingVision m\u00e8ne un changement radical dans la fa\u00e7on dont les maladies oculaires sont trait\u00e9es, allant au-del\u00e0 des th\u00e9rapies de correction d&#8217;un seul g\u00e8ne pour la r\u00e9tinite pigmentaire (RP), la maladie r\u00e9tinienne h\u00e9r\u00e9ditaire la plus courante affectant deux millions de personnes dans le monde.\u00a0<br>SparingVision a lev\u00e9 135 millions d&#8217;euros \u00e0 ce jour et a remport\u00e9 a \u00e9t\u00e9 r\u00e9compens\u00e9e dans le cadre du programme EIC Accelerator (instrument PME H2020 Phase 2, garantissant un financement non dilutif de 2,5 millions d\u2019euros). <br><br>Florence est fondatrice et Pr\u00e9sidente de MYRPHARM ADVISORS, une compagnie d\u2019accompagnement d\u2019entreprises aidant la recherche acad\u00e9mique translationnelle par la cr\u00e9ation de startups en sant\u00e9, la valorisation de l&#8217;innovation, le d\u00e9veloppement des affaires, la gestion de l&#8217;innovation, le financement, la strat\u00e9gie et la croissance.<br><br>Aux cot\u00e9s de Jean Pascal Traini\u00e9 (ALOE PRIVATE EQUITY),  Charles Beigbeder (AUDACIA) et de SORBONNE UNIVERSITE,, Florence est cofondatrice de SORBONNE VENTURE un fonds d&#8217;investissement deeptech. <br><br>Premier Prix Biotech de la Comp\u00e9tition Europ\u00e9enne CATAPULT 2019 (EITHealth)\u00a0<br>Finaliste du Prix Galien International, New York (US) &#8211; Med\u2019Startup, 2019<br><em>Membre du Comit\u00e9 de Surveillance des Investissements d\u2019avenir<\/em> 2019 <em>(SGPI\/Premier Ministre)<\/em><br>Laur\u00e9ate du Prix Mercure HEC Entrepreneurs 2018<br>Laur\u00e9ate du Prix Trajectoires HEC Au F\u00e9minin 2017<br>Laur\u00e9ate et Grand Prix du concours de cr\u00e9ation d\u2019entreprises innovantes i-LAB 2017<br>\u00c9lue \u00ab\u00a0Femme de l\u2019ann\u00e9e 2017\u00a0\u00bb par le magazine \u00e9conomique La Tribune<br><br><br><br><em>Florence Allouche Aknin<br>\u00a0<br>Florence is Pharmacist Doctor by training, and MBA from HEC Paris, mother of 4.<br>She began her career as biologist at AP-HP (Greater Paris Hospitals), then she held several positions in the diagnostics industry.<br>She created and managed for 16 years the Tech Transfer Office of AP-HP. 75 startups created that raised 1,5 b\u20ac.<br>Expert &amp; mentor at the main Paris\u2019s incubators, she represented French technology transfer at international level (AUTM, ASTP).<br>In 2016, Florence co-founded and was CEO of SPARINGVISION, a genomic medicines clinical stage company, developing a vision saving treatments for retinitis pigmentosa. SparingVision raised \u20ac130M and several European and French grants.<br>\u00a0<br>Florence is Professor at Faculty of Pharmacy &#8211; University Paris City, specialized in pharmaceutical innovation and entrepreneurship.\u00a0<br>She is\u00a0elected member of the French National Academy of Pharmacy.<br>\u00a0<br>Florence is President of MYRPHARM ADVISORS, a startup studio for startup creation, tech transfer, business development, innovation management, funding, strategy, growth, and mentoring.<br>\u00a0<br>With AUDACIA and ALOE Private equity\u00a0and Sorbonne University, Florence is\u00a0co founder of\u00a0SORBONNE VENTURE a \u20ac100M new\u00a0next gen deeptech\u00a0fund,\u00a0university and hospital backed dedicated to Deeptech \/ HealthTech.<br>\u00a0<br>Prev.\u00a0Member of the Watching Committee for the Big Investment Plan under the authority of French Prime Minister (SGPI)<br>First Prize Biotech at the European Startups Competition CATAPULT 2019<br>Finalist of the Prix Galien International, New York (US) &#8211; Med\u2019Startup, 2019<br>Mercure Entrepreneurs Award &#8211; HEC Paris 2019<br>Women Trajectory\u2019s Award &#8211; HEC Paris 2018<br>Elected &#8220;Woman of the Year 2017\u201d by the French financial magazine \u201cLa Tribune\u201d<\/em><\/span><\/div><div class=\"qubely-team-social-links qubely-team-icon-layout-normal qubely-team-icon-style-default\"><a href=\"https:\/\/twitter.com\/myrpharm\" class=\"qubely-team-social-twitter\" target=\"_blank\" rel=\"noopener noreferrer\"><i class=\"fab fa-twitter\"><\/i><\/a><a href=\"https:\/\/www.linkedin.com\/in\/florenceallouche\" class=\"qubely-team-social-linkedin\" target=\"_blank\" rel=\"noopener noreferrer\"><i class=\"fab fa-linkedin\"><\/i><\/a><\/div><\/div><\/div><\/div><\/div>\n\n\n\n<div class=\"wp-block-qubely-divider qubely-block-9a3ede\"><div class=\"qubely-block-divider \"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 240 40\" preserveAspectRatio=\"none\"><path d=\"M3.3 22.1c-.5-.2-.9-.5-1.3-.9-.3-.2-.5-.4-.8-.6.8-.7 1.5-1.3 2.3-2 .9-.7 1.8-1.6 2.4-2.6.1-.1.1-.2 0-.3-.1-.2-.3-.2-.5-.2-1.1.5-2 1.3-2.8 2.2-.8.9-1.7 1.7-2.5 2.5l-.1.1v.1c-.1.2-.1.5.2.6.5.3.9.5 1.4.8.4.3.9.6 1.2 1 .8.7 1.7 1.3 2.6 1.8.1.1.3 0 .4-.1.2-.1.2-.3.1-.5-.8-.8-1.6-1.4-2.6-1.9z\"><\/path><path d=\"M112.3 20c-4.5-.2-9-.3-13.5-.3-2.2 0-4.5-.1-6.7 0s-4.5.2-6.7.1c-4.5 0-9-.1-13.5-.2-1.1 0-2.2 0-3.4.1-1.1.1-2.2.1-3.4.2-2.2 0-4.5 0-6.7-.1-4.5-.1-9 0-13.5-.2-2.2-.1-4.5-.1-6.7 0s-4.5.3-6.7.3c-4.5.1-9-.1-13.5-.1s-9 0-13.5.2c-.1 0-.2.1-.2.2s.1.3.2.3c4.5.1 9 .2 13.5.2s9-.1 13.5-.1c2.2 0 4.5.2 6.7.3 2.2.1 4.5 0 6.7 0 4.5-.1 9 0 13.5-.2 2.2-.1 4.5-.1 6.7-.1 1.1 0 2.2.1 3.4.2 1.1 0 2.2.1 3.4.1 4.5-.1 9-.1 13.5-.2 2.2 0 4.5 0 6.7.1s4.5.1 6.7 0c4.5 0 9-.1 13.5-.3.1 0 .2-.1.2-.2 0-.2-.1-.3-.2-.3zM239.9 20.3c-.8-.9-1.7-1.7-2.5-2.6-.8-.9-1.7-1.7-2.8-2.2h-.3c-.2.1-.2.3-.1.5.6 1.1 1.4 1.9 2.4 2.6.8.6 1.5 1.3 2.3 2-.2.2-.5.4-.8.6-.4.3-.9.6-1.3.9-.9.5-1.8 1.2-2.5 2-.1.1-.1.2-.1.4.1.2.3.2.5.2 1-.5 1.9-1 2.6-1.8.4-.4.8-.7 1.2-1 .4-.3.9-.6 1.4-.8l.1-.1c0-.3.1-.6-.1-.7z\"><\/path><path d=\"M235.7 20.2c0-.1-.1-.3-.2-.3-4.5-.1-9-.2-13.5-.2s-9 .1-13.5.1c-2.2 0-4.5-.2-6.7-.3-2.2-.1-4.5 0-6.7 0-4.5.1-9 0-13.5.2-2.2.1-4.5.1-6.7.1-1.1 0-2.2-.1-3.4-.2-1.1 0-2.2-.1-3.4-.1-4.5.1-9 .1-13.5.2-2.2 0-4.5 0-6.7-.1s-4.5-.1-6.7 0c-4.5 0-9 .1-13.5.3-.1 0-.2.1-.2.2s.1.3.2.3c4.5.2 9 .3 13.5.3 2.2 0 4.5.1 6.7 0s4.5-.2 6.7-.1c4.5 0 9 .1 13.5.2 1.1 0 2.2 0 3.4-.1 1.1-.1 2.2-.1 3.4-.2 2.2 0 4.5 0 6.7.1 4.5.1 9 0 13.5.2 2.2.1 4.5.1 6.7 0s4.5-.3 6.7-.3c4.5-.1 9 .1 13.5.1s9 0 13.5-.2c.1 0 .2-.1.2-.2zM118.3 16.1c-.4.6-.8 1.2-1.1 1.8-.4.6-.4 1.3-.8 1.9l-.9 1.8c-.3.6-.5 1.3-.7 2 0 .2 0 .4.2.5.2.2.5.1.7-.1.4-.6.7-1.2 1-1.8.3-.6.5-1.3.8-1.9.2-.6.7-1.2.9-1.9.2-.6.5-1.3.6-2 0-.2 0-.3-.2-.4-.1-.1-.4-.1-.5.1zM124.4 16.1c-.4.6-.8 1.2-1.1 1.8-.4.6-.4 1.3-.8 1.9l-.9 1.8c-.3.6-.5 1.3-.7 2 0 .2 0 .4.2.5.2.2.5.1.7-.1.4-.6.7-1.2 1-1.8.3-.6.5-1.3.8-1.9.2-.6.7-1.2.9-1.9.2-.6.5-1.3.6-2 0-.2 0-.3-.2-.4-.1-.1-.3-.1-.5.1z\"><\/path><\/svg><\/div><\/div>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Conseil en strat\u00e9gie de transfert et de valorisation Advisor on transfer and valuation strategy Cr\u00e9e en 2020 Myrpharm Advisors vous accompagne dans le d\u00e9veloppement de vos innovations issues de la recherche acad\u00e9mique vers une validation leur permettant une mise sur le march\u00e9. Established in 2020, Myrpharm Advisors supports you in the development of your innovations [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"qubely_global_settings":"","qubely_interactions":"","footnotes":""},"class_list":["post-33","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.myrpharm.com\/index.php\/wp-json\/wp\/v2\/pages\/33","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.myrpharm.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.myrpharm.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.myrpharm.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.myrpharm.com\/index.php\/wp-json\/wp\/v2\/comments?post=33"}],"version-history":[{"count":12,"href":"https:\/\/www.myrpharm.com\/index.php\/wp-json\/wp\/v2\/pages\/33\/revisions"}],"predecessor-version":[{"id":198,"href":"https:\/\/www.myrpharm.com\/index.php\/wp-json\/wp\/v2\/pages\/33\/revisions\/198"}],"wp:attachment":[{"href":"https:\/\/www.myrpharm.com\/index.php\/wp-json\/wp\/v2\/media?parent=33"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}